- Home
- PPLI vs HCM Comparison
PPLI vs HCM Comparison
Compare PPLI & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PPLI | HCM |
|---|---|---|
| Founded | N/A | 2000 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.3B |
| IPO Year | 2020 | 2015 |
Fundamental Metrics
Financial Performance| Metric | PPLI | HCM |
|---|---|---|
| Price | $43.99 | $14.91 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 11 |
| Target Price | ★ $50.27 | $21.14 |
| AVG Volume (30 Days) | ★ 1.2M | 39.3K |
| Earning Date | 11-02-2026 | 07-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 79.97 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,365,235,000.00 | N/A |
| Revenue This Year | N/A | $14.11 |
| Revenue Next Year | $0.45 | $11.97 |
| P/E Ratio | ★ N/A | $5.49 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $34.79 | $9.77 |
| 52 Week High | $48.32 | $16.33 |
Technical Indicators
Market Signals| Indicator | PPLI | HCM |
|---|---|---|
| Relative Strength Index (RSI) | 66.77 | 58.76 |
| Support Level | $37.56 | $13.00 |
| Resistance Level | $47.96 | $15.55 |
| Average True Range (ATR) | 1.73 | 0.39 |
| MACD | 0.67 | 0.12 |
| Stochastic Oscillator | 97.70 | 78.46 |
Price Performance
Historical ComparisonAbout PPLI People Incorporated Common Stock
People Inc is a media and publishing business that operates a portfolio of brands, including PEOPLE, Food & Wine, Travel + Leisure, InStyle, Better Homes & Gardens, and Southern Living. The company also holds a minority equity stake in MGM Resorts International.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.